• Call(WhatsApp Us)

    +8615360806100
  • Email Us

    cherry@laeyo.com
  • 广州市花都区花山镇华辉路18号

    微观化妆品创意产业园E栋整栋

What to Verify Before Transferring a Men’s Face Cleanser Formula to a New Factory

Moving a men's face cleanser from one plant to another is a change-control event, not a file transfer. The INCI list can be identical and the product can still arrive thicker, thinner, harsher, less…

Category: Men Care Sourcing Guides • Author: laeyo • Published: 2026-11-01 • Views: 65

Moving a men’s face cleanser from one plant to another is a change-control event, not a file transfer. The INCI list can be identical and the product can still arrive thicker, thinner, harsher, less foamy, or unstable — because the water, the mixer geometry, the homogenizer energy, the raw-material grades and the fill line all changed at once. The job of the buyer is not to accept “same formula, same result.” It is to demand the evidence that proves equivalence: a signed golden reference, a bridged specification, stability and micro data on the new site’s bulk, and a packaging compatibility run on the actual tube or pump. This guide gives you the documents to request, the red lines not to cut, and a realistic timeline so you can qualify a new factory without discovering the problems after the first production run.

Why a Transfer Is a Reformulation in Practice

Even a “copy” formula behaves differently when four variables move. Map them before you talk price.

  • Water — purified water conductivity, microbial limits and hardness differ by site; surfactants are sensitive to ionic content.
  • Energy input — vacuum emulsifier vs atmospheric tank, anchor vs homogenizer, mixing speed and cooling rate change droplet size, viscosity and foam.
  • Raw materials — same INCI, different supplier grade, purity, impurity profile or physical form (flake vs bead) changes dissolution and skin feel.
  • Filling and packaging — a tube, airless pump or flip-top cap imposes its own rheology window and its own compatibility risk.

Because “clean” or “purifying” cannot be fully re-tested on every batch, qualified sites control performance through proxy metrics tied to the validated benefit — typically pH + viscosity + foam + sensory — tested per batch on approved methods, with a periodic performance study and revalidation triggered by any formula, process or raw-material change.

The Three Decisions to Lock Before You Transfer Anything

Everything downstream — testing cost, lead time, label artwork — is a consequence of these three. Lock them in writing, not in a call.

Decision to lock Why it drives cost and timeline Evidence to request before paying a deposit
Target market(s) and claim set Determines whether you need a CPSR and Responsible Person (EU), a filing (China), safety substantiation files (US), and which allergen declarations apply. A “global” launch multiplies documentation. Written market list per SKU; regulatory route confirmation per market; draft claim list reviewed against finished-product evidence.
Golden reference sample + full specification Without a signed reference, “matching the old product” has no measurable acceptance criteria and every trial becomes an opinion. Retained golden sample (with storage conditions), full spec with test methods, and the previous site’s last three batch records.
Packaging and fill line Viscosity must satisfy the pump or tube; incompatibility discovered after stability means repeating stability. Component drawings, resin/material declaration, and a packaging compatibility protocol agreed before the pilot run.

Minimum Document Pack to Request From the New Factory

Send this list as a single request. A factory that cannot answer items in sections A and B is not ready for a transfer.

A) Quality System and Change Control

  • Ask for: the site’s change-control procedure covering raw-material supplier change, equipment change and site transfer.
    Evidence: the controlled SOP plus a completed change-control record for your SKU.
    Acceptance criteria: the record explicitly addresses specification update, method bridging, golden sample re-signing, AQL review, process validation, performance revalidation and stability/micro impact — each marked as assessed, not blank.
  • Ask for: confirmation of who signs off before commercial production.
    Evidence: QA approval signature block, and a named customer-approval step if your contract requires it.
    Acceptance criteria: no bulk manufactured before documented QA release of the transfer.
  • Ask for: the rework and reprocess policy.
    Evidence: the SOP showing that out-of-spec bulk (for example viscosity out) requires a risk assessment covering stability, micro and performance impact before QA approval.
    Acceptance criteria: rework is never a verbal decision on the floor.

B) Testing and Substantiation

  • Ask for: stability data on the new site’s bulk and filled unit.
    Evidence: accelerated study (commonly 40 °C / 75% RH, 8–12 weeks), freeze–thaw cycling, and real-time data where available; parameters must include appearance, pH, viscosity, odour, phase separation and package integrity.
    Acceptance criteria: all results within the agreed specification, with the analytical methods named.
  • Ask for: microbiological data.
    Evidence: preservative efficacy / challenge test on the new bulk and micro counts per batch against the declared limits.
    Acceptance criteria: passing PET on the transferred formula, not a certificate borrowed from the old site.
  • Ask for: method bridging for pH, viscosity and foam.
    Evidence: spindle, speed, temperature and equipment listed for viscosity; calibration records for pH; the foam method definition.
    Acceptance criteria: the new site’s numbers are comparable to the golden reference on a bridged method, not a different one.
  • Ask for: human safety data where the claim set requires it.
    Evidence: HRIPT or patch test on the finished product from the new site, or a documented justification for not repeating it.
    Acceptance criteria: the decision to re-test or not is written and signed, not assumed.

C) Labelling and Claims Guardrails

  • Ask for: the fragrance and raw-material allergen declarations.
    Evidence: supplier allergen statements with calculated levels in the finished product.
    Acceptance criteria: allergens declared above the applicable threshold for the product type and market; label artwork updated accordingly.
  • Ask for: a claim-by-claim review against evidence.
    Evidence: a claims matrix mapping each label and listing claim to a test, study or ingredient rationale.
    Acceptance criteria: no claim on pack without a supporting document referenced in the matrix; mechanism-of-action claims about follicles or hair growth are removed.
  • Ask for: confirmation that no absolute promises are made.
    Evidence: written statement on what will not be claimed — global compliance, allergen-free, or a fixed performance duration.
    Acceptance criteria: conclusions are market-, formula- and test-condition-specific.

D) Traceability and Audit Readiness

  • Ask for: batch record structure and raw-material traceability.
    Evidence: a redacted example batch record showing lot numbers, weighings, in-process checks and yield reconciliation.
    Acceptance criteria: every input traceable to a supplier lot, and every in-process check has an acceptance range.
  • Ask for: COA and SDS for each raw material from the actual supplier used.
    Evidence: current documents matching the supplier named on the batch record.
    Acceptance criteria: no substituted supplier or grade without an approved change record.
  • Ask for: the site’s certification and last audit outcome.
    Evidence: GMP certificate (for example ISO 22716) with scope and validity dates, plus the latest internal or customer audit summary.
    Acceptance criteria: scope covers cleanser manufacture at the specific site and line.

Evidence Pack Summary

  • Signed golden reference sample with declared storage conditions.
  • Full finished-product specification with named test methods.
  • Completed change-control record for the transfer.
  • Accelerated and freeze–thaw stability report on the new site’s bulk.
  • Preservative efficacy test plus per-batch micro limits.
  • Method bridging report for pH, viscosity and foam.
  • Packaging compatibility protocol and results.
  • Fragrance allergen declaration with finished-product calculation.
  • Claims matrix with supporting evidence per claim.
  • Example batch record with traceability and in-process checks.
  • COA and SDS set matching the suppliers actually used.
  • GMP certificate and latest audit summary.

Match the Formula to the Plant: Process Equivalence

Ask the technical team to walk you through how the transferred formula behaves on their equipment, not how it behaved on yours.

  • Heating and cooling profile — cooling rate affects surfactant phase and final viscosity. Request the target profile and the tolerance.
  • Homogenization energy — over-shearing can thin the gel and trap air; under-shearing leaves lumps and unstable dispersion.
  • pH adjustment sequence — citrate or other buffers must be added at the same stage; adding acid hot versus cold changes viscosity and clarity.
  • Water specification — request conductivity and microbial limits for the site’s purified water, not a generic statement.
  • Scale — a 50 kg lab batch and a 2-tonne production batch are different products until proven otherwise. Insist on pilot-scale confirmation before commercial scale.

Packaging Compatibility: The Test Most Transfers Skip

A men’s face cleanser usually ships in a tube, an airless pump or a flip-top bottle, and each imposes constraints that stability testing alone will not catch.

  • Pump and valve performance — dose per stroke, prime time and suck-back must be verified with the actual bulk viscosity, at the start and end of use.
  • Fragrance–plastic interaction — fragrance components can migrate into polyolefins, causing odour shift, panel swelling or stress cracking; request a compatibility result, not an opinion.
  • Label adhesion — surfactant residue and humidity cause edge lift; specify the adhesive and test after stability storage.
  • Leak and drop testing — transport simulation on filled, capped units.
  • Headspace and evaporation — weight loss over storage indicates seal integrity.

Realistic Timeline for a Cleanser Transfer

Lead times below assume a cooperative factory and an existing formula. Compress documentation only where your market allows it.

Phase Buyer action Factory action Evidence output Typical lead time
1. Documentation and spec handoff Share formula, spec, golden sample, market list, claim list Review feasibility, gap-list open items Signed technical feasibility review 1–2 weeks
2. Lab trial and matching Approve or reject against golden reference Produce lab batches, adjust process Trial report with pH, viscosity, foam, sensory 2–4 weeks
3. Packaging lock Confirm component and decoration Order components, confirm fill window Approved component drawing and specification 3–6 weeks (component dependent)
4. Pilot run Attend or witness the run Manufacture pilot bulk, fill pilot units Pilot batch record and in-process data 1–2 weeks
5. Stability, micro, compatibility Review data as it lands Run accelerated stability, PET, compatibility Stability report, PET report, compatibility report 8–12 weeks (can overlap phase 6)
6. Label and claims review Approve artwork and claims matrix Provide allergen data, claim support Approved artwork with review record 2–4 weeks
7. Commercial run and handoff Approve release Manufacture, test, release COA, batch record, retention sample, final document pack 1–3 weeks

Fastest safe path: compress lab trials to a single round if the first trial matches the golden reference on all proxy metrics, run stability and packaging compatibility in parallel, and pre-approve artwork during the pilot. Do not compress the PET or the compatibility run.

Standard path: two trial rounds with a one-week sensory evaluation between them, sequential stability start after pilot approval, and a second compatibility check on production-filled units. Adds roughly four to six weeks and removes most late-stage surprises.

Red Lines: What Not to Cut

  • Do not skip preservative efficacy testing because “the preservative system is unchanged” — the water, the tank and the fill hygiene are new.
  • Do not accept a stability certificate from another site or another SKU as evidence for your bulk.
  • Do not skip packaging compatibility to save three weeks; a failed pump after launch costs far more.
  • Do not let viscosity be reported without the method — spindle, speed and temperature must be identical or bridged.
  • Do not allow a raw-material supplier substitution without a change record and an allergen re-check.
  • Do not approve claims you cannot evidence, and do not accept absolute promises about global compliance or allergen-free status.

Common Failure Modes and How to Prevent Them

Symptom Root cause Prevention Evidence to request
Bulk viscosity drifts between batches at the new site Different homogenizer energy and cooling rate; raw-material grade change Fix the process parameters in the master batch record and bridge the viscosity method Process parameters with tolerances; method bridging report; three consecutive batch results
Product thins or discolours after eight weeks Stability run performed on lab bulk, not production bulk, or only real-time data started after launch Run accelerated stability on pilot or production bulk before commercial release Accelerated and freeze–thaw report tied to the pilot batch number
Pump fails to prime, or doses unevenly Viscosity outside the pump’s design window; air trapped during filling Set a fill-viscosity window from the pump specification and test dose per stroke Pump specification; dose-per-stroke and prime-time test results on filled units
Odour shift or panel cracking within weeks Fragrance–plastic interaction not tested; incompatible resin or liner Run compatibility on the actual bulk and component, stored at elevated temperature Packaging compatibility report including odour, weight loss and visual inspection
Customs or retailer query on documentation COA, SDS or allergen declaration missing, expired, or mismatched to the supplier actually used Build a document pack per SKU before the first shipment and audit it quarterly Current COA/SDS set matched to batch records; allergen calculation; GMP certificate with scope
Label rejected for an unsupported claim Claims written by marketing after the artwork freeze, with no supporting test Freeze the claim list before artwork and require a document reference per claim Claims matrix signed by regulatory and QA
Micro out-of-spec on a single batch Water system or filling hygiene issue masked by a passing PET Trend per-batch micro counts and review water system validation Water system validation report; per-batch micro results; deviation record

Copy-Paste Checklist for Your Transfer Request

Share the target market list per SKU and confirm the regulatory route for each.
Provide the full formula, specification and test methods for the transferred product.
Attach the golden reference sample with its storage conditions and date.
Confirm the last three batch records from the current site are available.
Lock the claim list before artwork and reject claims without a supporting document.
Confirm which raw materials, grades and suppliers will be used at the new site.
Request COA and SDS for every raw material from those named suppliers.
Request the completed change-control record covering spec, method, golden sample and AQL.
Approve the method bridging plan for pH, viscosity and foam before the first trial.
Confirm the process parameters: heating and cooling profile, homogenizer energy, pH stage.
Run pilot-scale bulk before any commercial-scale commitment.
Test pH, viscosity, foam and sensory on every pilot and validation batch.
Start accelerated stability and freeze-thaw on pilot bulk, not lab bulk.
Confirm preservative efficacy testing is planned on the transferred formula.
Send the packaging drawings and agree the compatibility protocol.
Test dose per stroke, prime time, leak and label adhesion on filled units.
Request the fragrance allergen declaration and the finished-product allergen calculation.
Review label artwork against the allergen data and the claim matrix.
Confirm the rework and reprocess policy includes risk assessment and QA approval.
Request GMP certificate scope and the latest audit summary for the specific site.
Agree the final documentation handoff list and the release sign-off.
Schedule a quarterly document review after launch.

Frequently Asked Questions

If the formula is identical, do we really need new stability and micro testing?

Yes. Stability and microbiological performance belong to the bulk made at a specific site on specific equipment with that site’s water and hygiene controls. A report from the previous factory describes a different product. Accelerated stability, freeze–thaw and preservative efficacy testing on the new site’s pilot or production bulk are the minimum evidence for release.

Can the new factory match our existing viscosity and foam exactly?

Usually close, rarely identical without process adjustment. What matters is that the specification window accepts the new bulk and that the method is bridged — same spindle, speed and temperature for viscosity, and a defined foam method. If the product must work in an existing pump, set the fill-viscosity window from the pump specification and test dose per stroke on filled units.

Do we need to update regulatory files when a raw-material or fragrance supplier changes?

Treat it as a documented change. A fragrance supplier change can alter the ingredient profile and the allergen picture, which means the safety report, filings and label warnings may all need review, and a tolerance re-test should be assessed rather than assumed unnecessary. Have the factory produce a change assessment that explicitly covers exposure, ingredient risk, warning text and post-market monitoring.

How long does a men’s face cleanser transfer take end to end?

Plan on roughly 10 to 16 weeks for a straightforward transfer where the formula, components and claim set are already settled, with stability and compatibility running in parallel to artwork review. Component lead times and sequential stability can push this beyond 20 weeks. Any proposed timeline that skips preservative efficacy or packaging compatibility is not a shortcut — it is deferred risk.

What information gets us a faster, more accurate quote?

Target markets, SKU count and formats, positioning, packaging direction and your launch date. With those five items a manufacturer can scope testing, components and capacity without a round of clarification emails.

Informational only, not legal or regulatory advice. Confirm market-specific obligations with your regulatory specialist or Responsible Person before artwork sign-off.

Next Step

If you are transferring a men’s face cleanser or building a men’s care range from scratch, send your formula status, target markets, packaging direction and launch date in one message. You will get a scoped testing plan, a realistic transfer timeline and a documentation list matched to your markets — rather than a price with the evidence stripped out. Request a Quote.

Hi, I'm your LAEYO representative, hope you like this blog post.

With more than 20 years of experience in OEM/ODM/Private Label Cosmetics, I'd love to share valuable knowledge related to cosmetics & skincare products from a top-tier Chinese supplier's perspective.

  • Our team will answer your inquiries within 8 hours.
  • Your information will be kept strictly confidential.

Request received

Thanks — we’ve received your request. Our team will follow up shortly. we typically reply within 8 hours (often sooner).